Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06846268 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: May 31, 2027 to Dec 31, 2027
    • Study completion date: Oct 1, 2027 to Dec 31, 2027
    • Start date changed from estimate of Mar 1, 2025 to Apr 14, 2025
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single site, open-label, single-arm phase II study to determine feasibility, tolerability, and preliminary efficacy of neoadjuvant ADG126 and pembrolizumab in stage II or III colorectal cancer.
Trial Details
NCT Number NCT06846268
Lead Sponsor National University Hospital, Singapore
Collaborators: Adagene Inc
Conditions
(from sponsor)		 Locally Advanced Colorectal Cancer
Related terms Colorectal Neoplasms
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov